

Christoph Welsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3268625/publications.pdf>

Version: 2024-02-01

97
papers

2,798
citations

218381

26
h-index

189595

50
g-index

100
all docs

100
docs citations

100
times ranked

3743
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. <i>Hepatology</i> , 2009, 50, 1709-1718.	3.6	282
2	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
3	New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. <i>Gut</i> , 2012, 61, i36-i46.	6.1	168
4	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
5	Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. <i>Nature Medicine</i> , 2014, 20, 927-935.	15.2	130
6	Protease Inhibitor-Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus. <i>Gastroenterology</i> , 2011, 140, 667-675.	0.6	129
7	Pharmacokinetics of Peginterferons. <i>Seminars in Liver Disease</i> , 2003, 23, 023-028.	1.8	106
8	Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality. <i>Liver International</i> , 2018, 38, 645-653.	1.9	85
9	The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 856-865.	1.9	75
10	Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. <i>Genome Biology</i> , 2008, 9, R16.	13.9	74
11	Base Pairing between Hepatitis C Virus RNA and MicroRNA 122 3' of Its Seed Sequence Is Essential for Genome Stabilization and Production of Infectious Virus. <i>Journal of Virology</i> , 2012, 86, 7372-7383.	1.5	74
12	Class A Scavenger Receptor 1 (MSR1) Restricts Hepatitis C Virus Replication by Mediating Toll-like Receptor 3 Recognition of Viral RNAs Produced in Neighboring Cells. <i>PLoS Pathogens</i> , 2013, 9, e1003345.	2.1	73
13	Mutations in the MutS± interaction interface of MLH1 can abolish DNA mismatch repair. <i>Nucleic Acids Research</i> , 2006, 34, 6574-6586.	6.5	61
14	Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids. <i>Frontiers in Immunology</i> , 2018, 9, 723.	2.2	56
15	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100240.	3.0	50
16	Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response. <i>PLoS ONE</i> , 2017, 12, e0171755.	1.1	49
17	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. <i>Journal of Hepatology</i> , 2011, 55, 554-563.	1.8	47
18	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170.	6.1	47

#	ARTICLE	IF	CITATIONS
19	Cardiodynamic state is associated with systemic inflammation and fatal acute-to-chronic liver failure. <i>Liver International</i> , 2020, 40, 1457-1466.	1.9	46
20	Regulation of the Production of Infectious Genotype 1a Hepatitis C Virus by NS5A Domain III. <i>Journal of Virology</i> , 2011, 85, 6645-6656.	1.5	40
21	Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: A prospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0207162.	1.1	37
22	Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2006, 11, 507-519.	0.6	35
23	IL-22 and IL-22-Binding Protein Are Associated With Development of and Mortality From Acute-to-Chronic Liver Failure. <i>Hepatology Communications</i> , 2019, 3, 392-405.	2.0	33
24	Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants of the NS3 Serine Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1907-1915.	1.4	32
25	Structural and functional comparison of the non-structural protein 4B in flaviviridae. <i>Journal of Molecular Graphics and Modelling</i> , 2007, 26, 546-557.	1.3	29
26	Evolution of a Cell Culture-Derived Genotype 1a Hepatitis C Virus (H77S.2) during Persistent Infection with Chronic Hepatitis in a Chimpanzee. <i>Journal of Virology</i> , 2014, 88, 3678-3694.	1.5	27
27	HCV NS5A dimer interface residues regulate HCV replication by controlling its self-interaction, hyperphosphorylation, subcellular localization and interaction with cyclophilin A. <i>PLoS Pathogens</i> , 2018, 14, e1007177.	2.1	27
28	Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure. <i>Frontiers in Immunology</i> , 2020, 11, 534731.	2.2	26
29	Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX) by a real-time PCR assay. <i>Biomedical and Life Sciences</i> , 2009, 877, 4001-4006.	1.2	23
30	Clinical Significance of In Vitro Replication-Enhancing Mutations of the Hepatitis C Virus (HCV) Replicon in Patients with Chronic HCV Infection. <i>Journal of Infectious Diseases</i> , 2005, 192, 1710-1719.	1.9	21
31	Clinical relevance of HCV antiviral drug resistance. <i>Current Opinion in Virology</i> , 2012, 2, 651-655.	2.6	21
32	Novel Hepatitis C Drugs in Current Trials. <i>Clinics in Liver Disease</i> , 2008, 12, 529-555.	1.0	20
33	Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 865-873.	0.8	19
34	Association of HCV-related mixed cryoglobulinemia with specific mutational pattern of the HCV E2 protein and CD81 expression on peripheral B lymphocytes. <i>Blood</i> , 2004, 104, 1228-1229.	0.6	17
35	Peptidomimetic Escape Mechanisms Arise via Genetic Diversity in the Ligand-Binding Site of the Hepatitis C Virus NS3/4A Serine Protease. <i>Gastroenterology</i> , 2012, 142, 654-663.	0.6	17
36	Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2007, 38, 146-148.	1.6	16

#	ARTICLE	IF	CITATIONS
37	Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression. <i>Journal of Viral Hepatitis</i> , 2004, 11, 310-318.	1.0	15
38	Structural and functional analysis of a novel mutation of CYP21B in a heterozygote carrier of 21-hydroxylase deficiency. <i>Human Genetics</i> , 2005, 117, 558-564.	1.8	15
39	Will Interferon-Free Regimens Prevail?. <i>Gastroenterology</i> , 2012, 142, 1351-1355.	0.6	15
40	Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-infected patients. <i>Journal of Viral Hepatitis</i> , 2007, 14, 338-349.	1.0	14
41	Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases. <i>Journal of Viral Hepatitis</i> , 2007, 14, 484-491.	1.0	14
42	Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix 18. <i>Scientific Reports</i> , 2016, 6, 19526.	1.6	14
43	Identification and in silico characterization of a novel compound heterozygosity associated with hereditary aceruloplasminemia. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 1088-1094.	0.6	13
44	Evaluation of the MLH1 I219V alteration in DNA mismatch repair activity and ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 605-611.	0.9	13
45	Glycogen Synthase Kinase 3 β Enhances Hepatitis C Virus Replication by Supporting miR-122. <i>Frontiers in Microbiology</i> , 2018, 9, 2949.	1.5	13
46	Palmitoylation of Hepatitis C Virus NS2 Regulates Its Subcellular Localization and NS2-NS3 Autocleavage. <i>Journal of Virology</i> , 2019, 94, .	1.5	13
47	Capnography monitoring of non-anesthesiologist provided sedation during percutaneous endoscopic gastrostomy placement: A prospective, controlled, randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 401-407.	1.4	13
48	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1352.	2.2	13
49	RNA-Binding Activity of Hepatitis C Virus NS4B: A Novel Target for Small Molecule Inhibitors. <i>Gastroenterology</i> , 2009, 137, 2170-2172.	0.6	12
50	Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN- λ 2 induction by efficient MAVS cleavage. <i>Journal of Hepatology</i> , 2015, 62, 779-784.	1.8	12
51	Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol-analogs. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 183, 142-151.	1.2	12
52	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	1.0	12
53	Dimerization of the hepatitis C virus nonstructural protein 4B depends on the integrity of an aminoterminal basic leucine zipper. <i>Protein Science</i> , 2010, 19, 1327-1336.	3.1	11
54	Impact of Ribavirin on HCV Replicon RNA Decline during Treatment with Interferon- λ 2 and the Protease Inhibitors Boceprevir or Telaprevir. <i>Antiviral Therapy</i> , 2011, 16, 695-704.	0.6	11

#	ARTICLE	IF	CITATIONS
55	Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development. <i>Drug Discovery Today: Technologies</i> , 2014, 11, 19-25.	4.0	11
56	Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1263.	1.0	11
57	Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical Implications. <i>PLoS ONE</i> , 2016, 11, e0155337.	1.1	11
58	Clinical relevance of the 2'5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. <i>Journal of Hepatology</i> , 2009, 50, 49-58.	1.8	10
59	Contribution of charged and polar residues for the formation of the E1-E2 heterodimer from Hepatitis C Virus. <i>Journal of Molecular Modeling</i> , 2010, 16, 1625-1637.	0.8	10
60	Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors. <i>Journal of Biological Chemistry</i> , 2020, 295, 13862-13874.	1.6	10
61	Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation. <i>PLoS ONE</i> , 2019, 14, e0211537.	1.1	9
62	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. <i>Journal of Hepatology</i> , 2020, 73, 980-982.	1.8	8
63	Primary Actinomycosis of the Liver Mimicking Malignancy. <i>Zeitschrift Fur Gastroenterologie</i> , 2009, 47, 1062-1064.	0.2	7
64	Upregulation of the Long Noncoding RNA HULC by Hepatitis C Virus and Its Regulation of Viral Replication. <i>Journal of Infectious Diseases</i> , 2022, 226, 407-419.	1.9	7
65	Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia. <i>Gut</i> , 2021, 70, 221-222.	6.1	7
66	Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in patients naive to direct antivirals. <i>Antiviral Therapy</i> , 2014, 19, 455-461.	0.6	4
67	Application of Contrast-Enhanced Ultrasound to Detect Hepatic Hydrothorax in Patients with Liver Cirrhosis. <i>Ultraschall in Der Medizin</i> , 2020, , .	0.8	4
68	Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation. <i>PLoS ONE</i> , 2022, 17, e0263989.	1.1	4
69	Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site-directed mutagenesis of an NS4B aminoterminal basic leucine zipper. <i>Journal of Viral Hepatitis</i> , 2012, 19, 775-783.	1.0	3
70	High sustained virologic response rates in hepatitis C virus genotype 3 patients with and without cirrhosis treated with daclatasvir/sofosbuvir or velpatasvir/sofosbuvir ± ribavirin according to baseline resistance analysis. <i>Journal of Hepatology</i> , 2017, 66, S83.	1.8	3
71	Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	3
72	Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants. <i>Journal of Molecular Biology</i> , 2019, 431, 2354-2368.	2.0	3

#	ARTICLE	IF	CITATIONS
73	Comparison of Envelope 2 CD81 binding regions in PBMC-derived versus serum-derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates. <i>Journal of Viral Hepatitis</i> , 2011, 18, 181-192.	1.0	2
74	Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability. <i>Journal of Biological Chemistry</i> , 2021, 297, 101031.	1.6	2
75	Translation of IRF-1 Restricts Hepatic Interleukin-7 Production to Types I and II Interferons: Implications for Hepatic Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 581352.	2.2	2
76	SPCS1-Dependent E2-p7 processing determines HCV Assembly efficiency. <i>PLoS Pathogens</i> , 2022, 18, e1010310.	2.1	2
77	[654] PREDICTION OF VIROLOGIC RESPONSE IN HCV GENOTYPE 1A-INFECTED PATIENTS ACCORDING TO AMINO ACID PATTERN IN NS5A USING STATISTICAL LEARNING ALGORITHMS FOR CLASSIFICATION. <i>Journal of Hepatology</i> , 2007, 46, S247-S248.	1.8	1
78	616 EFFECT OF RIBAVIRIN ON THE FREQUENCY OF RNASE L CLEAVAGE SITES WITHIN THE HEPATITIS C VIRAL GENOME. <i>Journal of Hepatology</i> , 2009, 50, S226-S227.	1.8	1
79	754 IMPACT OF RIBAVIRIN ON SUBGENOMIC HEPATITIS C VIRUS RNA DECAY DURING TREATMENT WITH INTERFERON ALFA AND THE PROTEASE INHIBITOR TELAPREVIR. <i>Journal of Hepatology</i> , 2010, 52, S293-S294.	1.8	1
80	1240 ANALYSIS OF COMPLEX MUTATION PATTERNS IN THE HCV QUASISPECIES OF PATIENTS TREATED WITH TELAPREVIR OR BOCEPREVIR. <i>Journal of Hepatology</i> , 2011, 54, S490.	1.8	1
81	Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 803-811.	0.6	1
82	Regulatory Role of Phospholipids in Hepatitis C Virus Replication and Protein Function. <i>Pathogens</i> , 2022, 11, 102.	1.2	1
83	398 HCV-associated mixed cryoglobulinemia: Importance of mutations within the HCV E2 region and CD81 expression on peripheral B lymphocytes. <i>Journal of Hepatology</i> , 2004, 40, 118-119.	1.8	0
84	[66] MOLECULAR BASIS FOR VX-950 RESISTANCE. <i>Journal of Hepatology</i> , 2007, 46, S30.	1.8	0
85	348 HOMODIMERIZATION OF THE HEPATITIS C VIRUS NON-STRUCTURAL 4B PROTEIN REQUIRES AN INTACT BASIC LEUCINE ZIPPER. <i>Journal of Hepatology</i> , 2009, 50, S133-S134.	1.8	0
86	971 MOLECULAR MECHANISMS OF CROSS-RESISTANCE IN PEPTIDOMIMETIC PROTEASE INHIBITORS FOR STAT-C. <i>Journal of Hepatology</i> , 2009, 50, S352.	1.8	0
87	Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome. <i>Journal of Viral Hepatitis</i> , 2010, 17, 217-221.	1.0	0
88	776 GENETIC DIVERSITY IN THE LIGAND-BINDING SITE OF THE NS3.4A PROTEASE AND IMPACT ON PEPTIDOMIMETIC INHIBITORS IN HCV-1A. <i>Journal of Hepatology</i> , 2010, 52, S301-S302.	1.8	0
89	1348 VIRAL HETEROGENEITY IN HCV NS5A GENOME IS LOW IN PATIENTS WITH FAVORABLE IL28B GENOTYPES. <i>Journal of Hepatology</i> , 2011, 54, S532.	1.8	0
90	1214 MECHANISMS FOR KETOAMIDE ESCAPE IN VAL55 VARIANTS OF THE HCV NS3/4A PROTEASE DOMAIN. <i>Journal of Hepatology</i> , 2012, 56, S482.	1.8	0

#	ARTICLE	IF	CITATIONS
91	P1309 HCV MUTANTS RESISTANT TO MACROCYCLIC NS3-4A PROTEASE INHIBITORS SUPPRESS INTERFERON- β INDUCTION BY EFFICIENT MAVS CLEAVAGE. <i>Journal of Hepatology</i> , 2014, 60, S531.	1.8	0
92	Identification of glycogen synthase kinase 3 beta as a novel host factor of hepatitis C virus replication. <i>Journal of Hepatology</i> , 2017, 66, S321-S322.	1.8	0
93	Protease Inhibitor Resistance. , 2017, , 21-40.		0
94	Molecular mechanisms of fitness compensation in drug resistance-associated NS3 protease variants in hepatitis C. <i>Journal of Hepatology</i> , 2017, 66, S319.	1.8	0
95	THU-049-Impaired adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2019, 70, e181-e182.	1.8	0
96	Protease Inhibitor Resistance. , 2015, , 1-17.		0
97	Distinct clinical phenotypes in a family with a novel truncating MEN1 frameshift mutation. <i>BMC Endocrine Disorders</i> , 2022, 22, 64.	0.9	0